Compare AGIO & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | ORC |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2013 | 2011 |
| Metric | AGIO | ORC |
|---|---|---|
| Price | $35.65 | $6.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $38.88 | $7.50 |
| AVG Volume (30 Days) | 1.0M | ★ 4.7M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 17.07% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,011,000.00 | N/A |
| Revenue This Year | $76.75 | $21.28 |
| Revenue Next Year | $170.73 | $5.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.24 | $6.42 |
| 52 Week High | $46.00 | $8.40 |
| Indicator | AGIO | ORC |
|---|---|---|
| Relative Strength Index (RSI) | 74.22 | 51.57 |
| Support Level | $26.71 | $6.65 |
| Resistance Level | $36.07 | $7.45 |
| Average True Range (ATR) | 1.44 | 0.13 |
| MACD | 0.79 | 0.02 |
| Stochastic Oscillator | 98.76 | 97.18 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.